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Abstract
Screening rates for cancer related genetic mutations are low in the primary care setting, despite
evidence-based guidelines recommending screening in all patients who meet criteria. Genetic
mutations, such as the breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations,
drastically increase breast and ovarian cancer risk in patients. The United States Preventive
Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN)
provide evidence-based guidelines on criteria for genetic testing in women at risk for breast and
ovarian cancer related gene mutations. Primary care providers (PCPs), including advanced
practice registered nurses (APRNs), are at the front lines of preventative care in the community
and should participate in preventative genomic care. Increased adherence to evidence-based
guidelines promotes improved patient safety and outcomes. The purpose of this Doctor of
Nursing Practice (DNP) project was to increase genetic testing rates to improve early detection
and prevention of breast and ovarian cancer in women. This was accomplished through a quality
improvement project at a women’s health primary care outpatient clinic. A new practice protocol
was introduced that incorporated evidence-based guidelines for both cancer risk assessment and
genetic testing. After the Cancer Risk Assessment and Genetic Testing Protocol (CRA/GTProtocol) was implemented, baseline genetic testing rates were compared to intervention phase
genetic testing rates to evaluate usefulness of the protocol. Results demonstrated that the protocol
was successful at reducing practice barriers to genetic testing and created a more stable cancer
risk assessment system. Further research and interventions are needed to continue to reduce
barriers to genetic testing in primary care to promote early detection and prevention of cancer.
Keywords: genetic testing, cancer related gene mutations, early detection of cancer,
cancer prevention, quality improvement project, breast and ovarian cancer in women
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Chapter 1
Background and Significance
According to the American Cancer Society (ACS), approximately one in eight women
will develop breast cancer in their lifetime and one in 78 will develop ovarian cancer (ACS,
2019; ACS, 2021). The majority of cancers appear to be random or sporadic; however, 5-10% of
breast cancers and 15% of ovarian cancers are caused by inherited genetic mutations (ACS,
2019; ACS, 2021). Testing for these gene mutations can be a useful tool in early detection and
prevention of breast and ovarian cancer in women.
Both genetic and environmental factors can increase risk of cancer. Genetic mutations
acquired due to environmental factors are the most common cause of cancer. Damage is done to
genes in a particular cell, like a breast cell, which can then divide many times and form a tumor.
These mutations can be caused by tobacco, aging, radiation, and other environmental factors
(ACS, 2019). Germline mutations that cause inherited cancers are less common. These mutations
are passed directly from a parent to a child at the time of conception; they can pass from
generation to generation. Although it is not always possible to predict acquired mutations,
germline mutations can easily be identified, leading to improved prevention and early detection
of cancer.
BRCA1/2 gene mutations drastically increase breast and ovarian cancer risk in patients.
Up to 72% of women with a BRCA1 gene mutation and 69% of women with a BRCA2 gene
mutation will develop breast cancer during their lifetime (Kuchenbaecker et al., 2017). Up to
44% of women with a BRCA1 gene mutation and 17% of women with a BRCA2 gene mutation
will develop ovarian cancer during their lifetime (Kuchenbaecker et al., 2017). Having these
gene mutations can increase lifetime breast cancer risk from about 13% to 72% and lifetime
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ovarian cancer risk from 1.3% to 44%. Harmful BRCA1/2 gene mutations are responsible for
many cancers; however, if the mutations are identified early, life-saving risk-reducing
interventions can be implemented.
ACS research from 1989 to 2017 shows that improvements in early detection and
treatment of breast cancer reduced the number of women who died from breast cancer by 40%
(DeSantis et al., 2019). Early detection of cancer saves lives, because treatment is most
successful when breast and ovarian cancer is found at an early stage. Many risk-reducing
screenings, medications, surgeries, and treatments exist to aid in early detection and prevention
of breast and ovarian cancer in carriers of BRCA1/2 mutations.
Genetic testing for germline mutations is an important component of preventative care
and can alter cancer screening and treatment recommendations (Hamilton, 2017). Genetic testing
is not a new concept; forms of genetic testing existed in the 1950s and have been evolving ever
since. BRCA1/2 mutation screening has been available for over 20 years. Researchers, scientists,
and medical professionals are working to make these life-saving preventative tests more
available, more affordable, and more useful to everyday care management. The USPSTF and
NCCN both provide national evidence-based guidelines that recommend genetic testing for
germline mutations in high-risk individuals and how to determine that risk.
Providers who care for women in an outpatient primary care setting are at the front line
for assessing cancer risk and ensuring patients with higher risk receive appropriate interventions.
Despite this, many high-risk women in primary care settings are under-tested and providers are
unable to accurately tailor screenings and interventions to patients potentially carrying harmful
mutations (Silver et al., 2019). Barriers to genetic testing have been identified among patients,
providers, and practice systems. PCPs are called to eliminate barriers to genetic testing and
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follow evidence-based guidelines to improve patient safety and outcomes (Bednar et al., 2018;
Campion et al., 2019; Hamilton et al., 2017). Using genetic testing as a preventative care tool can
save the lives of patients and family members and enhance community health and wellness.
Problem Statement
Despite the existence of evidence-based guidelines promoting genetic testing in primary
care, many PCPs continue to not order genetic testing for patients considered high-risk for cancer
related gene mutations. Genetic testing rates are very low in primary care settings (Silverman et
al., 2018). Low testing rates are often associated with patient, provider, and system barriers.
Common barriers reported by patients that should be addressed by providers include concerns
with cost and usefulness of testing (Kne et al., 2017; Smith-Uffen et al., 2021). Provider and
system barriers hindering genetic testing include lack of genomic training and understanding of
guidelines, feeling underqualified to order and interpret tests, and no practice protocols to
promote guideline adherence and continuity of care (Hamilton et al., 2017; Nair et al., 2017).
Inconsistent cancer risk assessment, genetic testing, and referrals to genetic counseling in
primary care results in poor patient outcomes.
This gap in clinical practice leaves the high-risk population vulnerable to potential missed
or late cancer diagnosis, causing harmful outcomes. PCPs are not practicing safe care when they
allow patients carrying harmful gene mutations to only participate in preventative care measures
recommended to the average population. BRCA1/2 mutation carriers need additional riskreducing interventions to ensure early detection and prevention of breast and ovarian cancer.
Purpose Statement
The purpose of this DNP project was to increase the genetic testing rates in women at
high-risk for breast and ovarian cancer related gene mutations in a primary care setting by
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focusing on reducing system barriers. A new protocol was created and implemented for a
primary care clinic to increase guideline adherence for cancer risk assessment, genetic testing,
and referrals to genetic counseling. The staff members at the clinic were trained on the new
protocol to reduce system barriers. When high-risk patients participate in appropriate genetic
testing, providers are not only following evidence-based guidelines, but ensuring patients receive
accurate preventative care and interventions. This preventative care measure aids in early
detection and prevention of cancer and ultimately improves patient safety and outcomes.
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Chapter 2
Review of Literature
A literature review was conducted to examine topics related to genetic testing as a tool
for early detection and prevention of breast and ovarian cancer, as well as benefits and barriers to
genetic testing. Databases that were searched include: PubMed, CINAHL, and ProQuest. Key
terms that were utilized in searches included: evidence-based guidelines related to genetic
testing, cancer risk assessment, genetic testing, cancer related gene mutations, BRCA1 and
BRCA2, early detection and prevention of cancer, women, breast and ovarian cancer, patient
barriers to genetic testing, provider barriers to genetic testing, practice barriers to genetic
testing. Hundreds of articles were found during the searches and narrowed down by topic
relevance and inclusion and exclusion criteria. Inclusion criteria included: peer-reviewed
journals, articles published between 2017 and 2021, and articles published in an academic or
scholarly journal. Exclusion criteria included: articles not printed in the English language and
full text not available. Remaining articles were included in this literature review.
Evidence-Based Guidelines
The literature review revealed two major evidence-based guidelines that guide cancer risk
assessment and genetic testing related to breast and ovarian cancer among women. These two
major guidelines are the USPSTF and NCCN guidelines, which are used in the project and
defined herein. Both guidelines focus on BRCA1/2 mutation testing, but recognize the benefits
of multigene testing when appropriate.
Several risk factors for BRCA1/2 gene mutations that have been identified and guide
criteria for testing include: personal or family history of breast cancer under the age of 50,
Ashkenazi Jewish ancestry, invasive ovarian cancer, male breast cancer, high-grade prostate
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cancer, pancreatic cancer, multiple family members with breast cancer, and a family member
with a known BRCA1/2 mutation (Daly et al., 2021; USPSTF et al, 2019). In risk assessment,
first-degree and second-degree relatives are included, i.e., children, siblings, parents,
grandparents, aunts/uncles, nieces/nephews, and grandchildren. If any of these red flags are
noted during routine collection of personal and family history, a cancer risk assessment tool can
aid in determining their risk for carrying a harmful BRCA1/2 gene mutation and the
appropriateness of testing for mutations.
The USPSTF guidelines state that women who present with personal or family history
associated with a higher risk of carrying a BRCA1/2 gene mutation should first be screened with
a validated cancer risk assessment tool to determine risk level, then receive genetic testing and
genetic counseling if classified as high-risk, which is considered a B level recommendation
(USPSTF et al., 2019). Through research by USPSTF et al. (2019), sufficient evidence was
found to support moderate level benefits associated with cancer risk assessment and genetic
testing and counseling in high-risk women. Evidence was found to recommend against genetic
testing and counseling in women who do not meet high-risk criteria due to the small level of
benefits or no benefits identified for these women (USPSTF et al., 2019). The USPSTF
guidelines state that genetic testing and genetic counseling is not recommended for women who
are not at high-risk for carrying a BRCA1/2 gene mutation, which is considered a D level
recommendation (USPSTF et al., 2019). Per the NCCN guideline, genetic testing is also not
recommended in persons less than 18 years of age (Daly et al., 2021).
Both guidelines recommend discussing benefits, risks, and limitations of testing with
patients prior to genetic testing (Daly et al., 2021; USPSTF et al, 2019). Sufficient evidence was
found to support that harms associated with cancer risk assessment, genetic testing and
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counseling, and related care management interventions are small to moderate (USPSTF et al.,
2019). PCPs should be aware of risks to better allow patients to make an educated decision about
testing.
Both guidelines recommend appropriate referrals to genetic health providers for care
management and counseling if the provider ordering the test has limited genomic knowledge and
the patient tests positive for a harmful gene mutation (Daly et al., 2021; USPSTF et al, 2019).
PCPs can participate in preventative genomic care and manage patients within their scope of
practice. Patients carrying gene mutations associated with high prevalence of cancer should
receive proper specialty care related to their risk. The guidelines support providers assessing risk,
testing, counseling, and managing care to their level of training and education.
Cancer Risk Assessment Tools
Cancer risk assessment tools evaluate personal and family history to determine risk for
carrying a gene mutation. High-risk individuals meet criteria for genetic testing and counseling
as a preventative care measure. In research done by the USPSTF, seven different tools were
evaluated and found to accurately estimate the likelihood of carrying a BRCA1/2 gene mutation.
All seven risk assessment tools are considered validated instruments and the USPSTF found
advantages and limitations to each individual tool and found insufficient evidence to recommend
one tool over another (USPSTF et al., 2019). The seven validated tools are: the International
Breast Cancer Intervention Study instrument, also called the Tyrer-Cuzick, the Manchester
Scoring System, the Pedigree Assessment Tool, the 7-Question Family History Screening Tool,
the Referral Screening Tool, the Ontario Family History Assessment Tool, and brief versions of
the BRCAPRO. The USPSTF evaluated and found the National Cancer Institute Breast Cancer
Risk Assessment Tool, also called the NCI-Gail Model, is not useful in determining risk of gene
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mutations and should not be used for this purpose (USPSTF et al., 2019). Cancer risk assessment
tools rely on accurate family history; the USPSTF guidelines do not offer any solutions to
assessing risk in a woman with unknown family history (USPSTF et al., 2019). These cancer risk
assessment tools are recommended for use by PCPs with little to no genomic training to guide
appropriate genetic testing and referrals to genetic counselors (USPSTF et al., 2019).
Benefits of Genetic Testing
Genetic testing for gene mutations allows providers to safely manage care for a patient.
Benefits and motivating factors that exist for patients to participate in genetic testing and
counseling include: predicting cancer risk, predicting cancer behaviors, informed disease
management, and family health (Smith-Uffen et al., 2021). If an individual tests positive for
carrying a harmful gene mutation, recommended screenings and interventions are impacted for
the patient and their family. Individualized care plans centered around patient needs promote
safety and improved patient outcomes.
Improved Patient Outcomes
Carriers of BRCA1/2 gene mutations are not only at a higher risk of developing breast
cancer and ovarian cancer, but also fallopian tube and peritoneal cavity cancer, pancreatic
cancer, gallbladder cancer, and prostate cancer (Samadder et al., 2019). Patients at high-risk for
cancer can detect cancer earlier and even prevent cancer with appropriate screenings and
interventions. Risk-reducing interventions include screenings, medications, surgeries, and
treatments.
Benefits of Preventative Screening. Screening interventions specific to breast cancer
include breast self-awareness, clinical breast examinations, breast ultrasounds, mammography,
and breast magnetic resonance imaging (MRI). Ovarian cancer screenings include clinical pelvic

8

examinations with bimanual palpation of the ovaries, transvaginal ultrasound, and serum cancer
antigen 125 (CA-125) testing. Early detection of cancer increases treatment options and
decreases cancer related deaths. Screening guidelines are established for the general population
and altered for individuals at higher risk of developing cancer. The more screening opportunities
that are available to a patient, the more likely it is to detect cancer at an earlier, more treatable
stage.
In a qualitative descriptive study done by Puzhko et al. (2019), benefits were shown to
adopting personalized breast cancer screening plans per individual needs. The study found
existing screening guidelines often follow a “one-size-fits-all” approach, and that many higherrisk individuals do not receive proper screening (Puzhko et al., 2019). The study demonstrated
that providers need further genomic training to appropriately build individualized cancer
screening plans (Puzhko et al., 2019).
Ovarian cancer is not screened for in the general population and breast cancer is often
screened with mammography alone. The NCCN guidelines support regular transvaginal
ultrasound and CA-125 testing for ovarian cancer screening in patients positive for BRCA1/2
gene mutations until able to receive risk-reducing surgery (Elezaby et al., 2019). The addition of
breast MRI screening to annual mammography improves early detection of cancer. Detection of
breast cancer with MRI screening has a sensitivity ranging from 75% to 91% and specificity of
82% to 93% compared to a lower sensitivity of 25% to 59% and specificity of 91% to 99% with
mammography alone (McClintock et al., 2020). A patient with a gene mutation that has not yet
been identified, does not receive safe and appropriate screening.
Benefits of Preventative Surgery. Surgical treatments of established breast cancer
include a lumpectomy, removing cancerous tissue and the surrounding tumor margin, and a
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mastectomy, removing all breast tissue. The recommended preventative surgical intervention for
patients carrying a BRCA1/2 gene mutation is a prophylactic bilateral mastectomy (Samadder et
al., 2019). A risk-reducing bilateral mastectomy decreases breast cancer rates by 90% (Samadder
et al., 2019).
Surgical treatment of established ovarian cancer often requires a total hysterectomy,
removing the cervix, uterus, fallopian tubes, ovaries, and any affected surrounding tissue. The
recommended preventative surgical intervention for patients carrying a BRCA1/2 gene mutation
is a prophylactic bilateral salpingo-oophorectomy, removing ovaries and fallopian tubes
(Samadder et al., 2019). A risk-reducing bilateral salpingo-oophorectomy reduces the risk of
developing ovarian cancer by 80% and the risk of developing breast cancer in premenopausal
women by 50% (Samadder et al., 2019). Education on the risks and benefits of surgery as a
preventative measure should be discussed with patients. For example, female patients in
childbearing ages who wish to continue to have children should wait to receive a bilateral
salpingo-oophorectomy until after childbearing is complete.
Benefits of Preventative Medications and Treatments. Many of the same methods
used to treat cancer can also be used to prevent cancer or cancer recurrence in those at high-risk.
Randomized placebo-controlled studies have found that risk-reducing medications, such as
tamoxifen, raloxifene, and aromatase inhibitors, reduce the risk of estrogen-positive breast
cancer in women (Samadder et al., 2019). While in childbearing ages, but not while actively
trying to conceive a child, the use of oral contraceptives can reduce the risk of ovarian cancer by
over 40% (Samadder et al., 2019). Radiation therapy to the breast reduces the risk of cancer
recurrence by 50% at 10 years and the risk of death by 20% at 15 years (ACS, 2019).
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Cancer Treatment Benefits. In patients who have been diagnosed with breast or ovarian
cancer, surgeries, medications, and treatments are influenced by the presence of a BRCA1/2
mutation. Samadder et al. (2019) studied the use of Olaparib as chemotherapy compared to
standard chemotherapy use as a treatment for metastatic breast cancer in women positive for a
BRCA1/2 mutation. The response rates to Olaparib were doubled, and the risk of disease
progression or death was 42% lower when compared to standard chemotherapy (Samadder et al.,
2019). When harmful gene mutations are identified, patient safety and outcomes are improved
with more effective cancer interventions through informed disease management.
Other Patient Benefits. In a retrospective chart review done by Breit et al. (2020), of the
women who received genetic testing and did not have an identified gene mutation, 51% were still
classified as high-risk with elevated lifetime risks of developing breast cancer. This study
concluded that a negative genetic test result does not determine lack of cancer risk, and care
management changes are often still recommended in persons with no germline mutation present
(Breit et al., 2020). Women who are carriers of BRCA1/2 gene mutations should participate in
genetic counseling and decide which screenings and interventions are best for them. Women at
high-risk for developing cancer, who are not carriers of harmful gene mutations, should also
discuss with providers on what screenings and interventions are best for them to aid in early
detection and prevention of cancer. Individualizing care based on risk leads to safer care and
improved patient outcomes.
Improved Family Outcomes
In a systematic review by Smith-Uffen et al. (2021), one of the top motivating factors for
a patient to participate in genetic testing was to benefit family members. The American College
of Obstetricians and Gynecologists (2018) recommends cascade testing, or performing genetic
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testing and counseling for blood relatives of individuals identified as carriers of harmful gene
mutations. Cascade testing should be offered in a timely manner to improve safety and outcomes
of family members. Each family member that also tests positive for the gene mutation will have
the same benefits of early detection and prevention of cancer as the patient. One patient who
participates in genetic testing and counseling can improve the lives of countless others.
Utilization of Genetic Testing in Clinical Practice
According to USPSTF guidelines, all women in a primary care setting should be screened
for personal or family history indicative of harmful gene mutations related to breast and ovarian
cancer and receive appropriate genetic testing and counseling if determined high-risk (USPSTF
et al., 2019). Silverman et al. (2018) found that despite the increased availability of genetic
testing and the USPSTF guidelines recommendation, genetic testing rates are exceptionally low
in primary care. In a study involving 3055 women in a primary care setting, 369 (12%) women
met USPSTF guidelines for genetic testing, and only 17 (4.6%) women received testing or
counseling (Silverman et al., 2018). The other 352 (95.4%) high-risk women did not receive
appropriate genetic testing and counseling and were unable to participate in risk-reducing
interventions.
In clinical practice, primary care genetic testing rates are lower than testing rates among
specialties such as oncology and gynecology. Evidence found by Silver et al. (2019) showed that
BRCA1/2 testing in clinical practice is not in agreement with current guidelines. Their study
involving 20,758 women not limited to a primary care setting, using a multinomial logistic
regression, found 27.1% of high-risk women who met NCCN guidelines for genetic testing did
not receive testing (Silver et al., 2019). Women who could have benefited from live-saving
interventions did not receive the opportunity.
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Research suggests that many harmful gene mutations are not identified in clinical practice
due to testing limitations and more than just high-risk patients should receive testing. A study by
Beitsch et al. (2019) involving 959 patients with breast cancer, found half of patients who tested
positive for a harmful gene mutation would not have been identified if guidelines alone had been
followed for genetic testing. In their study, all patients underwent multigene testing whether they
met guidelines for testing or not. A total of 8.65% of the patients tested positive for a genetic
mutation that increased risk for breast cancer. Of the 959 patients, 49.95% met NCCN guidelines
for testing and 9.39% of them tested positive. Of the other 50.05% who did not meet guidelines
for testing, 7.9% of them still tested positive for a harmful mutation (Beitsch et al., 2019). The
difference in positive results (p=.424) between the two groups was not statistically significant
(Beitsch et al., 2019). They recommended all patients with a diagnosis of breast cancer should
have multigene testing done regardless of risk (Beitsch et al., 2019). Genetic testing is beneficial
to patients with a cancer diagnosis to more safely manage care.
Barriers to Genetic Testing
Low genetic testing rates in primary care impede early detection and prevention of
cancer. In the previously mentioned study by Silver et al. (2019), most eligible patients did not
receive genetic testing and counseling due to a lack of provider recommendation and cost of
testing. Several barriers to genetic testing have been identified among patients, providers, and
practices that can be addressed.
Patient-Centered Barriers
In the same study by Silver et al. (2019) involving 20,758 women, those who did not
have health insurance were less likely to opt for testing. Conversely, those with graduate or
professional degrees were more likely to agree to testing (Silver et al., 2019). In a systematic
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review by Smith-Uffen et al. (2021) about studies related to genetic testing barriers, the top
barriers identified included concerns about cost, confidentiality, and usefulness of the results. In
one of the studies, 87.7% of the high-risk patients were interested in genetic testing that was free,
64.8% were interested in genetic testing that cost $150, and only 20% were interested in genetic
testing that cost $1500 (Smith-Uffen et al., 2021). As cost and availability of genetic testing
continues to improve, providers must educate high-risk patients on the benefits of testing.
In a study by Hurtado-de-Mendoza et al. (2017) involving 50 Black women with a
previous breast or ovarian cancer diagnosis, phone interviews were conducted to assess testing
rates. Only 48% of the women were referred for genetic testing and counseling after receiving
their diagnosis (Hurtado-de-Mendoza et al., 2017). In the study, younger (p=.01) patients showed
higher genomic knowledge and higher genomic knowledge (p=.006) was significantly associated
with higher testing rates (Hurtado-de-Mendoza et al., 2017). The study identified low testing
rates in high-risk Black women, especially among those with higher age or lower genomic
knowledge.
According to Hurtado-de-Mendoza et al. (2018), Latinas, who have the second highest
prevalence of BRCA1/2 gene mutations, have fewer genetic testing discussions with providers
and are more frequently under-tested compared to non-Hispanic White patients. The study used
semi-structured interviews with 20 providers who cared for Latina patients and identified barriers
to testing including language, cost, and genomic awareness (Hurtado-de-Mendoza et al., 2018).
Providers need to be sensitive to patient needs and encourage access to appropriate resources to
eliminate barriers.
Kne et al. (2017) used focus groups to identify barriers to testing in 603 adult women
considered high-risk for genetic mutations who met NCCN guidelines for genetic testing and
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counseling. All 603 women were mailed a referral letter recommending genetic counseling and
only 50 (8%) of the high-risk women completed a consultation with a genetic counselor (Kne et
al., 2017). In a focus group including 30 women who did not attend an appointment, barriers
which influenced their decision not to seek genetic counseling included limited knowledge about
genetic counseling, concerns about the genetic counseling process, and concerns about cost and
insurance coverage (Kne et al., 2017). In a focus group including 10 women who did attend an
appointment, facilitating factors identified included discussions with providers about genetic
counseling services and improved follow-up from their provider (Kne et al., 2017). Genetic
testing and counseling rates are improved with adequate patient-provider communication and
follow-up.
Provider Barriers
In a study by Nair et al. (2017), 369 primary care providers were surveyed to assess their
knowledge of cancer risk assessment and accuracy of identifying high-risk patients qualified for
genetic testing. The highest correct response rate among all the knowledge and clinical
application questions was only 53% (Nair et al., 2017). The study revealed providers had limited
knowledge of genetic mutations that increase risk of breast and ovarian cancer and were not able
to correctly recognize which patients were at high-risk and qualified for genetic testing (Nair et
al., 2017). To compensate for these knowledge-gaps, validated cancer risk assessment tools
should be used in primary care to better identify patients at high-risk for gene mutations.
Hamilton et al. (2017) used a systematic review of 27 studies about provider knowledge
and attitudes towards genetic testing to identify barriers to genetic testing. The top provider
barriers identified in PCPs included lack of guideline understanding and feeling underqualified to
order and interpret tests (Hamilton et al., 2017). The study recommended the implementation of
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programs to increase provider genomic knowledge to help engage PCPs in cancer risk
assessment, genetic testing, and appropriate referrals as a preventative care measure (Hamilton et
al., 2017). Increasing primary care provider genomic knowledge and understanding of evidencebased guidelines aids in increased genetic testing rates and safe care management of high-risk
patients.
Practice Barriers
Clinical practice is different at each clinic and among each provider. Evidence-based
guidelines are established to guide care and ensure safety of all patients. Clinics often have
systems in place to promote adherence to guidelines, but many practice barriers affect genetic
testing rates. A study by Bobbili et al. (2020) that used a retrospective medical chart review,
found that providers ordered more BRCA1/2 genetic tests when a genetic counselor was present
at the practice compared to practices without a genetic counselor. Good access to genetic
counselors improves appropriate referrals. While most primary care clinics do not have genetic
counselors in office, similar protocols and practices can be adopted to improve genetic testing
rates.
Bednar et al. (2018) used semi-structured interviews at 16 clinics to assess for practice
barriers related to genetic testing to create a quality improvement project to reduce barriers and
increase genetic testing rates and adherence to national guidelines. Many barriers were identified
including inconsistent collection of family history, inconsistent ordering of genetic tests, lack of
tracking genetic testing and results, patient no-shows for genetic testing and reviewing results,
inconsistent referrals to genetic counselors, poor availability of genetic counseling appointments,
inability to track referrals to genetic counseling and ensure patients attended appointment,
difficulty locating past genetic test results in electronic medical record systems, and staff turn-
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over (Bednar et al., 2018). All practice barriers led to decreased genetic testing rates and referrals
to genetic counseling (Bednar et al., 2018). Eliminating practice barriers can promote safe care
and improved patient outcomes through adherence to evidence-based guidelines.
Bobbili et al. (2020) performed a retrospective medical chart review to assess compliance
with guidelines, including 410 adult patients with breast cancer who met NCCN guidelines for
genetic testing. Of the providers, 97% were Oncologists with specific training and knowledge in
NCCN guidelines and genetic testing, 67% had genetic counselors in office, and all clinics
involved had established methods for collecting family history, assessing mutation risk, and
ordering genetic testing (Bobbili et al., 2020). Of the 410 high-risk patients, 94% had BRCA1/2
testing completed (Bobbili et al., 2020). Primary care genetic testing rates are lower than testing
rates among specialties such as oncology. This study demonstrated that high testing rates are
possible with appropriate training and practice systems that promote guideline adherence.
Role of the APRN in Genetic Testing
In the past, all genetic services were performed by medical geneticists and genetic
counselors. Advancements in technology that resulted in reduced costs of testing and increased
public awareness have led to a higher demand for testing (Campion et al., 2019). To meet the
growing demand, genetic testing, interpreting results, and care management are now performed
by non-genetic physicians, APRNs, and physician assistants in addition to medical geneticists
and genetic counselors. Campion et al. (2019) found a need for non-genetic providers to increase
genomic education, participate in interdisciplinary collaboration, and understand when to refer to
genetic providers for appropriate care management.
The United States currently has 4,000 genetic counselors, or less than one counselor for
every 80,000 people (Himes & Shuman, 2020). APRNs in a primary care setting must be
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prepared to identify high-risk patients, perform genetic testing, and appropriately refer to genetic
counseling. Himes and Shuman (2020) recommend that all patients who test positive for a
harmful gene mutation in primary care be referred for genetic counseling to receive specialty
care. APRNs are an important part of the genomic interdisciplinary team.
In a study by Yoes and Thomas (2020), a shortage of genetic counselors in the United
States was identified and an APRN-led program was implemented and assessed for usefulness in
bridging the gap. The APRNs participated in cancer risk assessment, genetic testing and
counseling, care management, and appropriate referrals. The study determined that APRNs
delivered and maintained high-quality genetic care to the rural population in need (Yoes &
Thomas, 2020). APRNs with appropriate genomic education are qualified and encouraged to
deliver preventative care interventions to promote early detection and prevention of cancer.
Summary of Literature Review
Evidence-based guidelines have been established to guide appropriate cancer risk
assessment, genetic testing, and referrals to genetic counseling for breast and ovarian cancer
related gene mutations. Research found that adherence to guidelines improves patient safety and
outcomes through early detection and cancer prevention interventions. Identification of harmful
gene mutations can save the lives of patients and their family members.
Barriers were identified to guideline adherence for genetic testing and counseling
including patient-centered barriers, provider barriers, and practice barriers. Providers can reduce
barriers through participating in genomic education, engaging in patient-provider
communication, and establishing a practice system that promotes guideline adherence and
continuity of care. Special attention is required to ensure appropriate genetic services are
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provided to all patients equally to avoid disparities among different races and socioeconomic
statuses.
Genetic testing rates are significantly lower within primary care compared to oncology.
Preventative care measures are intended to aid in identifying and reducing risk prior to receiving
a cancer diagnosis and needing oncology services. Early detection and prevention of cancer is
hindered when harmful gene mutations have not yet been identified. PCPs, including APRNs,
need to follow evidence-based guidelines and participate in safe preventative care through cancer
risk assessment, genetic testing, and referrals to genetic counselors. This DNP project focused on
reducing practice barriers to genetic testing and guideline adherence to improve patient safety
and outcomes.
Needs Assessment
Based on the available literature, genetic testing rates are sub-optimal in clinical practice
among primary care settings. Genetic testing is associated with improved patient safety and
outcomes related to early detection and prevention of cancer. A prospective practice gap analysis
and baseline data collection were used in the needs assessment of this DNP project.
Population Identification
The identified population was adult women 18 years of age or older within an outpatient
primary care setting who met high-risk criteria that qualified them for genetic testing. Genetic
testing is often completed in other healthcare settings; however, for the purposes of this project,
the testing was used as a preventative care measure and preventative care primarily takes place
under the direction of a PCP in an outpatient primary care setting. The age was determined based
on guidelines which recommend against genetic testing in minors. For this population, the term
“woman” refers to female sex assigned at birth.
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Key Stakeholders
The main stakeholder was the woman who qualified for genetic testing. The patient’s
current care management and future health is directly influenced by the presence of a harmful
cancer-related gene mutation. Other stakeholders included the families of the patient, the
providers and organization caring for the patient, and the community.
With any positive result, the question of “which other family members are also positive
for this mutation?” arises due to the germline nature of these mutations. Identifying gene
mutations in one patient can aid in successfully identifying the same mutation in family members
as well. Providers are better able to build care management and preventative screening regimens
for patients when more information is available to them. This makes the provider and the
organization more successful in their goal of providing safe and quality care to patients. The
more patients who are informed of their own family history and cancer risk, the more aware the
community will be of cancer risk.
Organizational Assessment
In a retrospective data collection, baseline data was collected from the outpatient clinic
from January 2021 to November 2021. Data included: the number of women ages 18-65 who
presented for a well-woman or new patient examination per month, the number of patients who
completed cancer risk assessments per month, the number of patients who qualified for
BRCA1/2 genetic testing per USPSTF or NCCN guidelines per month, and the number of
patients who completed genetic testing per month. Cancer risk assessment rates and genetic
testing rates were both very inconsistent month to month; assessment rates ranged from an
average of 8.7% to 63.5% per month and genetic testing rates ranged from an average of 22.7%
to 60.0% per month (Table 1). The mean genetic testing rate was 37.9% and the mean cancer risk
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assessment rate was 30.8%; both displayed low adherence to evidence-based guidelines (Table
1). Data showed that not every high-risk patient who qualified for genetic testing had genetic
testing ordered for them by a provider. Data also revealed that not every patient who presented
for a well-woman or new patient examination completed a cancer risk assessment.

Table 1
Baseline Cancer Risk Assessment and Genetic Testing Data
Month

Patients

Assessments Rate

Qualified

Tested

Rate

Jan 2021
Feb 2021
Mar 2021
Apr 2021
May 2021
Jun 2021
Jul 2021
Aug 2021
Sept 2021
Oct 2021
Nov 2021
Total

218
334
344
299
241
320
253
298
302
339
316

115
212
126
54
86
39
44
26
124
83
96

34
58
26
15
22
14
18
15
34
33
32

10
24
13
9
5
6
8
5
15
10
9

29.4%
41.4%
50.0%
60.0%
22.7%
42.9%
44.4%
33.3%
44.1%
30.3%
28.1%
37.9%

52.8%
63.5%
36.6%
18.1%
35.7%
12.2%
17.4%
8.7%
41.1%
24.5%
30.4%
30.8%

Note. Baseline data collected from January 2021 to November 2021.

A practice prospective gap analysis was used to identify gaps in practice related to
baseline data. Informal conversations were conducted with providers about their knowledge and
confidence surrounding their pre-intervention cancer risk assessment and genetic testing
practices. The conversations revealed a sufficient general knowledge of the importance of cancer
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risk assessment and genetic testing in women at risk for breast and ovarian cancer related gene
mutations. Several providers agreed that ordering tests and reviewing results with patients was
inconsistent and they would be interested in learning how to improve this process. Although a
need for continual education always exists, no sufficient gap was identified in provider
knowledge of care management or use of referrals post genetic testing at this time.
Informal conversations with the office manager, front-office staff, and medical assistants
revealed employee turnover and unclear roles were the largest culprits to inconsistent screening
and testing rates. Another factor included a perceived lack of time to ensure patients completed
the cancer risk assessment. Several staff members recognized that they were not following any
particular protocol or procedure related to cancer risk assessments and agreed that completing
related tasks is inconsistent.
The gap analysis revealed a practice system failure. The two main gaps in practice
included inconsistent cancer risk screening of patients and inconsistent testing of qualified highrisk patients. These two gaps in care were addressed by this DNP project.
Available Resources Assessment
The clinic already had an instrument for cancer risk assessment screening in place, an
established relationship with a genetic testing company to order genetic testing, and appropriate
access to local genetic counselors and specialists for referrals. The cancer risk assessment
instrument was a Tyrer-Cuzick risk model questionnaire used to determine lifetime breast cancer
risk, likelihood of carrying a BRCA1/2 gene mutation, and appropriateness of genetic testing.
The USPSTF has determined this model a validated and useful tool to estimate risk (USPSTF et
al., 2019). No gaps were identified in available tools and resources.
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Cost
The student was unable to complete a cost analysis. There was no anticipated change in
cost to the patients and the project did not incur any additional cost to the practice. The value of
the time required by staff members to implement and follow a new protocol was not measurable.
Scope of Project
The scope of this DNP project was to create a detailed protocol for cancer risk
assessment and genetic testing for a clinic and orient staff members to the protocol. The project
was designed to benefit all key stakeholders by limiting system barriers to genetic testing. The
intervention influenced genomic preventative care services administered to women at the clinic.
Project Goals
The mission of this DNP project was to directly increase patient safety and outcomes by
improving adherence to evidence-based guidelines to increase genetic testing rates among
qualified high-risk individuals. The specific goals of this DNP project were to increase genetic
testing rates from a baseline of 38% to a goal of 80%, increase cancer risk assessment rates from
a baseline of 31% to a goal of 80%, and improve practice genomic care patterns. The objectives
of this DNP project included creating a practice protocol, orienting staff members to the new
protocol, providing support to staff members, and tracking data throughout the intervention
phase to assess for goal attainment.
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Chapter 3
Theoretical Framework of Project
The goal of this DNP project was to increase compliance with evidence-based guidelines
to ensure safety and quality of care. This was done by means of a quality improvement project.
The theoretical framework for this project was Kurt Lewin’s Change Theory, in which a threestep model is used to aid in the change process: unfreezing, moving, and refreezing (Burnes,
2020). Lewin introduced the idea that every person, group, and organization is in a constant state
of “quasi-stationary equilibrium,” or in a temporary state with the potential to change. The
unfreezing, moving, and refreezing steps assist in unlocking that potential and paving the way for
positive, lasting change.
Unfreezing, Moving, and Refreezing
If change is desired, the current thought or behavior needs to be unfrozen from its current
state of quasi-stationary equilibrium and destabilized (Burnes, 2020). Once the thought or
behavior is destabilized, it needs to be moved with “action research.” Lewin stated that there is
“no research without action, no action without research” (Burnes, 2020, p. 40). Action research
involves finding the “why” behind the change and aligning the change to the identified needs or
goals of the person, group, or organization. In this theory, agency is key to actualizing change. If
all parties involved do not agree to the change, obstacles will arise and true change cannot take
place. The moving step needs to address the barriers to change and work at aligning the agency
of individuals. The final step, refreezing, is the process of reinforcing the new quasi-stationary
equilibrium after the change has been introduced. All affected parties should be involved in the
decision making of the change to ensure successful refreezing.
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Application to Project
To appropriately apply Lewin’s Change Theory to this DNP project, all three steps were
incorporated. The practice was divided into three groups, front-office staff, medical assistants,
and providers. Each group of the organization could be affected differently by the change and
each member within the groups could react differently to the change. The behaviors and thoughts
of each individual, among the three groups, and within the organization as a whole, were studied
with an action research mindset to determine how this change would affect each department and
what each department needed to contribute in order to make the change successful. Thoughts and
attitudes of different group members were assessed in informal conversations to predict
resistance and acceptance. All three groups expressed hesitancy to change due to a perceived
lack of time.
Unfreezing took place during the orientation to the new protocol; the practice gaps and
needs were discussed with a call to action. Making each group aware of the “why” behind the
change aided in aligning agency and desire to change. Moving took place as the new protocol
was implemented, with each group learning their part in the change. The moving phase took time
and patience, so support was provided throughout the process. The perceived lack of time was
addressed and the hesitancy to change dissolved as the intervention phase continued. Refreezing
took place throughout the intervention phase to ensure a smooth transition to the new protocol.
Refreezing also took place when the change was reinforced after the intervention phase by
reviewing the new data that positively supported the change as beneficial. This allowed for
prolonged impact and sustained change.
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Summary of Theoretical Underpinnings
Change is often met with resistance. Lewin’s Theory of Change is designed to help
predict the resistance and obstacles, discover necessary steps and tools to combat the resistance,
and smoothly transition to the new normal to achieve desired outcomes and benefits. Change
occurs when driving forces overcome the restraining forces (Burnes, 2020). All members of an
organization play a key role in quality improvement projects and ensuring continual growth and
progression.
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Chapter 4
Project Plan
The goal of this project was to increase genetic testing rates among high-risk patients to
improve patient safety and outcomes. In order to obtain this goal, the student performed a quality
improvement project that addressed two identified practice gaps. The gaps included inconsistent
cancer risk screening of patients and inconsistent genetic testing of qualified high-risk patients.
The project setting was Ma’am Exams, an outpatient women’s health primary care clinic in a
suburb of the Phoenix Metropolitan Area within the state of Arizona. The clinic primarily serves
a patient population of women between the ages of 18-65, which made it an ideal location for
this project.
PICOT Question
The project plan used the population, intervention, comparison, outcome, time (PICOT)
question format. The PICOT format was used to develop a clinical research question that was
answerable (Melnyk & Fineout-Overholt, 2019). The specific PICOT question for this project
was: In women, 18-65 years of age presenting for a well-woman or new patient examination,
who qualify for genetic testing of breast and ovarian cancer related gene mutations, does the
implementation of the CRA/GT-Protocol improve the rate of qualified women being tested?
Population
The designated population for this project included women ages 18-65 in an outpatient
women’s health primary care setting that met high-risk criteria and qualified for genetic testing.
Patients included those who presented for a well-woman or new patient examination. Cancer risk
screening is considered a preventative care measure and related personal and family history is
typically collected and updated during annual well-woman and new patient examinations. For
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those patients who may have completed a cancer risk assessment the prior year, annual updates
are recommended due to the continuously changing nature of personal and family history. The
age range was chosen because genetic testing is discouraged in minors by the guidelines, and the
clinic selected for the project does not typically serve women over the age of 65.
Intervention
The intervention was a quality improvement project that addressed the identified practice
gaps to improve practice patterns and procedures to ensure the population received safe and
quality care. The goal of the project was to improve cancer risk assessment rates from 31% to
80% and genetic testing rates from 38% to 80%. The intervention included a new practice
protocol, staff orientation to the protocol, and staff support during the intervention phase.
The CRA/GT-Protocol was developed using evidence-based guidelines from the NCCN
and USPSTF. The protocol was approved by the Medical Director and the Office Manager of the
clinic. The CRA/GT-Protocol included a cancer risk assessment procedure, a genetic testing
procedure, and a patient follow-up tracking procedure (see Appendix A).
The staff members involved included the front-office personnel, the medical assistants,
and the providers. A training session was provided to orient all staff members to the protocol
prior to the implementation phase. The protocol orientation was performed at a mandatory lunch
training one week prior to the intervention phase. The situation, background, assessment,
recommendation (SBAR) format was used to introduce the protocol at the training session (see
Appendix B). The training session lasted approximately 45 minutes.
On December 1, 2021 the intervention phase began and all staff members were expected
to follow the new protocol. The intervention phase lasted three months, from December 2021 to
February 2022. Throughout the intervention phase, support was provided to the staff members by
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the student and questions about the protocol were answered. After the first and second months
within the intervention phase, the student provided the new data to staff members to display
progress. After the last month of the intervention phase, the final data was made available to the
staff members to reinforce and sustain the change.
Tools and Resources. No changes were made to the cancer risk assessment instrument
used, type of genetic testing ordered, or the genetic counselors and specialists used for referrals.
Comparison
In order to determine whether or not the project was successful, pre-intervention practice
patterns, assessment rates, and testing rates were compared to the intervention phase practice
patterns, assessment rates, and testing rates. Data used for analysis included: the number of
women ages 18-65 who presented for a well-woman or new patient examination per month, the
number of patients who completed cancer risk assessments per month, the number of patients
who qualified for BRCA1/2 genetic testing per USPSTF or NCCN guidelines per month, and the
number of patients who completed genetic testing per month. For comparison purposes, 11
months of baseline data was included−January 2021 through November 2021−and three months
of intervention phase data was included−December 2021 through February 2022.
Outcome
The expected outcome of this project was an improvement in practice patterns, cancer
risk assessment rates, and genetic testing of qualified women. This project was designed to
ultimately improve patient outcomes and safety by consistently following evidence-based
guidelines in practice. Other predicted outcomes included improved early detection and
prevention of cancer, improved family safety and outcomes, and improved awareness of cancer
risk among the community.
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Time
The DNP project timeline spanned from September 2021 to April 2022. The intervention
phase took place from December 1, 2021 to February 28, 2022. The following is an overview of
the project timeline:
•

September: Clinical site approval obtained to carry out DNP project

•

September: DNP project proposal was defended and approved by committee

•

October: Submitted DNP project proposal to the institutional review board (IRB)

•

November: Obtained approval from the IRB to carry out DNP project

•

November: Performed SBAR lunch protocol orientation with staff

•

December-February: Project intervention phase

•

December-March: Collected and analyzed data

•

March: Final DNP project was defended and approved by committee

•

April: Submitted final DNP project to the University of Nevada, Las Vegas (UNLV)
Graduate College

Risks, Limitations, and Threats
One risk included a possible variation in the number of patients scheduled during the
intervention phase; a recent global pandemic has had a negative influence on in-person office
appointments. For data evaluation, the total number of patients seen per month was not
compared, rather the number of patients who qualified for testing compared to the number of
patients who completed testing was used to account for differences in patient volume per month.
Another limitation was staff-member agency and resistance to change, or unwillingness to
participate in the intervention phase. Lewin’s Change Theory was selected as the theoretical
framework for this project to combat resistance to change and ensure a more successful
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implementation of the new protocol. Other threats included patients refusing to complete the
cancer risk assessment, perform ordered genetic testing, or return to the clinic to review test
results with a provider. These threats influenced both the baseline and intervention phase data
equally. Ultimately, patient agency was acknowledged and respected by the student and this
project was designed to focus on addressing system barriers at this time.
Institutional Review Board Approval
Per requirements set by UNLV School of Nursing, the project was reviewed by the
Biomedical IRB at UNLV prior to implementation. The approved DNP project proposal was
submitted to the IRB in October 2021. The project was determined exempt by the IRB (see
Appendix C). No patient protected health information (PHI) was collected, analyzed, or
evaluated in this project. De-identified aggregate data was used for baseline and intervention
phase data comparison and evaluation. The data was collected from the electronic medical record
(EMR) system used by the clinic and de-identified and aggregated prior to evaluation. Access to
raw numerical data that may have contained PHI was completed only by employees of the clinic
with rights to access the data for patient care. The student obtained approval from the clinic to
use the de-identified aggregate data for the purposes of a quality improvement project to improve
patient care at the clinic (see Appendix D).
Evaluation Plan
In order to answer the PICOT question, the DNP project was evaluated by comparing
intervention phase data to baseline data. Data that was collected included: the number of women
ages 18-65 who presented for a well-woman or new patient examination per month, the number
of patients who completed cancer risk assessments per month, the number of patients who
qualified for BRCA1/2 genetic testing per USPSTF or NCCN guidelines per month, and the
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number of patients who completed genetic testing per month. All data was de-identified
aggregate data and no PHI was used for evaluation. The implementation of the CRA/GTProtocol was intended to improve practice patterns and limit system barriers by addressing the
two identified practice gaps including: inconsistent cancer risk screening rates and inconsistent
genetic testing rates. The cancer risk assessment procedure and genetic testing procedure within
the protocol were each evaluated for an increase in quantity and consistency month to month. To
assess overall goal attainment, the mean baseline cancer risk assessment rate and the mean
baseline genetic testing rate were expected to improve and reach a goal of 80% during the
intervention phase. A trend analysis was used to assess for improvements in practice patterns to
predict sustainability of the achievement. The intervention was considered successful if
evidence-based guidelines were followed more frequently and consistently to improve patient
safety and outcomes.

32

Chapter 5
Summary of Implementation
According to the ACS (2022a; 2022b), it is estimated that over 56,000 women will die
from breast or ovarian cancer in the United States in 2022 alone. Many of those cancers are
caused by harmful gene mutations that can be identified through genetic testing. Genetic testing
rates are very low within the primary care setting, where the majority of preventative care should
be taking place. Increasing the identification of high-risk individuals and performing the
recommended genetic testing will improve patient safety and outcomes.
The purpose of this project was to reduce practice barriers to genetic testing by
implementing a more stable system for cancer risk assessment and genetic testing to promote
early detection and prevention of breast and ovarian cancer in women. A new practice protocol
was designed and implemented during a lunch training session using the SBAR format. The
protocol focused on increasing appropriate cancer risk assessment and genetic testing according
to evidence-based guidelines.
Threats and Barriers
The largest barrier to this project’s success was patient compliance. Informed consent
should be obtained prior to genetic testing and patient autonomy must be maintained. If a patient
chose not to complete the cancer risk assessment or genetic testing recommended by the
provider, then their decision was respected. Patient compliance was not directly addressed by
this project.
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Results
Data Collection
Data from EMR reports was collected in monthly increments during the intervention
phase including: the number of women ages 18-65 who presented for a well-woman or new
patient examination per month, the number of patients who completed cancer risk assessments
per month, the number of patients who qualified for BRCA1/2 genetic testing per USPSTF or
NCCN guidelines per month, and the number of patients who completed genetic testing per
month. The intervention data and baseline data were compiled for analysis (Table 2).

Table 2
Baseline and Intervention Cancer Risk Assessment and Genetic Testing Data
Month

Patients

Assessments Rate

Qualified

Tested

Rate

Jan 2021
Feb 2021
Mar 2021
Apr 2021
May 2021
Jun 2021
Jul 2021
Aug 2021
Sept 2021
Oct 2021
Nov 2021
Dec 2021
Jan 2022
Feb 2022
Total

218
334
344
299
241
320
253
298
302
339
316
248
223
235

115
212
126
54
86
39
44
26
124
83
96
197
206
220

34
58
26
15
22
14
18
15
34
33
32
39
22
33

10
24
13
9
5
6
8
5
15
10
9
18
11
11

29.4%
41.4%
50.0%
60.0%
22.7%
42.9%
44.4%
33.3%
44.1%
30.3%
28.1%
46.2%
50.0%
33.3%
39.0%

52.8%
63.5%
36.6%
18.1%
35.7%
12.2%
17.4%
8.7%
41.1%
24.5%
30.4%
79.4%
92.4%
93.6%
41.0%

Note. Baseline data collected from January 2021 to November 2021 and intervention data
collected from December 2021 to February 2022.

34

Data Analysis
Two c-charts and three p-charts were created using the raw data to perform a trend
analysis and evaluate for improvements in practice patterns. The 11 baseline data points were
compared to the three intervention phase data points. The p-value was identified for both the
cancer risk assessment rate per month and the genetic testing rate per month. Each of the five
charts were analyzed and are described below.

Figure 1
Cancer Risk Assessment Rate per Month

Note. The percent of patients per month that completed a cancer risk assessment from those who
attended a new patient or well woman examination.
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A statistically significant improvement in the cancer risk assessment rate per month was
found during the intervention phase (p<.001). The baseline average of 30.76% assessments
completed per month increased to an average of 88.24% per month, passing the goal of 80%
(Figure 1). Baseline data points fall outside both the upper and lower control limits, indicating an
unstable system or inconsistent cancer risk assessments. Intervention phase data points fall
within the upper and lower control limits displaying increased consistency and a more stable
system. A more consistent assessment system creates higher accuracy of identifying patients at
high-risk for genetic mutations.

Figure 2
Number of Patients Qualified per Month

Note. The number of patients per month that took a cancer risk assessment that were determined
high-risk for a harmful genetic mutation and qualified for genetic testing.
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The number of qualified patients per month increased from a baseline average of 27.4
high-risk patients to an average of 31.3 high-risk patients during the intervention phase (Figure
2). This data represents nearly four additional high-risk patients identified per month that were
missed with previous cancer risk assessment practices. Again, baseline data points do not all fall
within the upper and lower control limits, suggesting a previously inconsistent assessment
system that improved during the intervention phase.

Figure 3
Qualified Rate per Month

Note. The percent of patients per month that qualified for genetic testing from those who
completed a cancer risk assessment.
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The qualified rate per month dropped from a baseline average of 29.98% to an average of
15.09% in the intervention phase (Figure 3). This change was statistically significant (p<.001).
This data suggests that in the previous provider-led decision practice, providers were more likely
to screen patients that appeared to qualify for genetic testing and did not screen patients that were
assumed to be low-risk. However, more individuals qualified for genetic testing per month
during the intervention phase (Figure 2), suggesting that the provider-led decision practice was
not consistently accurate. The more consistent system-led decision practice takes the
“randomness” out of the monthly qualifying rate. The intervention phase data points all fall
within the upper and lower control limits displaying more consistency and stability. The
intervention phase average of 15.09% is a more accurate representation of how many individuals
qualify for genetic testing per month among the population.
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Figure 4
Genetic Testing Rate per Month

Note. The percent of patients per month that completed genetic testing from those who qualified
for genetic testing.

No statistically significant change was found in the testing rate per month (p=.417). The
testing rate per month did increase from an average of 37.87% at baseline to an average of
42.55% during the intervention phase, but did not reach the goal of 80% (Figure 4). Patient
compliance with recommended genetic testing was not significantly affected by this intervention.
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Figure 5
Number of Patients Tested per Month

Note. The number of patients per month that completed genetic testing.

The total number of patients who completed genetic testing per month increased from an
average of 10.4 at baseline to an average of 13.3 during the intervention phase (Figure 5). The
average testing rate per month was sustained with the increase in qualified individuals (Figure 4),
suggesting that as more individuals qualify for genetic testing, the total number of patients who
complete genetic testing will continue to increase. This data represents an average of nearly three
additional individuals receiving genetic testing per month who were previously missed during
baseline practice patterns. The more high-risk individuals who participate in genetic testing, the
more harmful gene mutations are identified and lifesaving interventions can be implemented.
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Discussion
The trend analysis revealed a significant shift in cancer risk assessment patterns from a
provider-led decision practice to a system-led decision practice. This practice pattern change
increased the total number of patients identified as high-risk individuals for genetic mutations
that can cause breast and ovarian cancer. Implementing the CRA/GT-Protocol was effective in
reducing practice barriers and creating a stable system with more consistent and accurate results.
The total number of patients who completed genetic testing per month on average
increased during the intervention phase. As more patients were identified as high-risk for genetic
mutations and qualified for genetic testing, more individuals had the opportunity to participate in
genetic testing. This preventative care measure can lead to early detection and prevention of
breast and ovarian cancer in women.
Limitations
Unlike the cancer risk assessment rate that surpassed the goal of 80%, the genetic testing
rate did not reach the goal of 80%. Unfortunately, the CRA/GT-Protocol intervention did not
impact the genetic testing rate as originally hypothesized. Reducing system barriers did not
significantly affect patient compliance. Further research and interventions are needed to reduce
patient barriers, such as their beliefs and attitudes towards genetic testing. This project was an
initial step towards increasing genetic testing rates at a primary care clinic and continued quality
improvement interventions are required to ultimately reach the goal.
Project Sustainability
The CRA/GT-Protocol has been successfully implemented at the clinic. This protocol is
expected to continue to produce more consistent cancer risk assessment rates and an increased
total number of patients participating in genetic testing throughout the coming years. Updates to
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the protocol may be necessary as further research results in updated evidence-based guidelines.
The protocol will be reviewed, with other practice protocols, on an annual basis as part of the
clinic’s quality improvement standards to ensure preventative care measures are being met.
Appropriate cancer risk assessment and genetic testing can reduce practice liability and promote
safe preventative care.
Future Scholarly Activity
The goal of this project was to improve genetic testing rates among high-risk individuals,
especially within the primary care setting. This project focused on reducing practice barriers to
influence testing rates, but did not address patient barriers to genetic testing. Further research and
interventions are needed to address patient barriers to genetic testing to continue to increase
testing rates. The CRA/GT-Protocol can be used as a pattern for other clinics to aid in reducing
practice barriers to genetic testing. This should be used in conjunction with measures to reduce
provider barriers and patient barriers to genetic testing as well. The protocol and project process
can also be used as a pattern for other quality improvement projects that focus on system
improvements.
Dissemination of Results
The project results have been shared with staff members of the clinic to reinforce the
need for a sustainable system that produces consistent results. The CRA/GT-Protocol was
accepted by the Office Manager and Medical Director of the clinic and is expected to continue to
benefit the patient population. The results from this project have been disseminated through
publication to a student dissertation database and the student will continue to work towards
publishing the project in a peer-reviewed scholarly journal for review by other healthcare
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professionals. Results were also disseminated through a poster presentation at the 2022 Western
Institute of Nursing Conference and a podium presentation with the Nevada Nurses Association.
Conclusion
This project has highlighted the importance of a system-led decision practice pattern
rather than provider-led decisions in regards to cancer risk assessments. A stable system
produces consistent results in order to more accurately identify individuals at high-risk for
harmful gene mutations. Individuals at high-risk for genetic mutations should have the
opportunity to receive genetic testing and appropriate genetic counseling in order to more fully
understand their cancer risk and available interventions and treatment options. Genetic testing
rates remain low within primary care. Quality improvement projects, such as this, are needed to
make changes to practice and increase compliance with genomic evidence-based guidelines.
Identifying harmful genetic mutations leads to improved patient safety and outcomes by
increasing early detection and prevention of cancer.
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Appendix A

CANCER RISK ASSESSMENT AND GENETIC TESTING PROTOCOL
PRACTICE CANCER RISK ASSESSMENT PROCEDURE:
All adult women patients presenting for a new patient or well woman examination, who have any personal or family
history of cancer, should complete the cancer risk assessment. The cancer risk assessment identifies high-risk
individuals who qualify for genetic testing per USPSTF or NCCN guidelines.
PRACTICE GENETIC TESTING PROCEDURE:
All high-risk individuals should receive genetic testing. The provider discusses genetic testing with the patient during
their preventative care visit and orders appropriate genetic testing. Sample collection should occur the same day if
possible. Once testing is completed, the results need to be reviewed with the patient by a provider. The provider will
update patient records and update appropriate screening and care management recommendations. All individuals who
test positive for a harmful gene mutation should be referred to a Genetic Counselor and/or Specialists.
PRACTICE PATIENT FOLLOW-UP TRACKING PROCEDURE:
All high-risk individuals should have progress tracked and receive follow-up to ensure genetic testing is completed,
test results are reviewed with a provider, and appropriate referrals are sent. A communication encounter in the EMR is
used to track patient progress. The encounter is closed after all steps have been completed.
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Appendix B

SBAR PROTOCOL ORIENTATION
SITUATION:
Screening rates for cancer related genetic mutations are low in the primary care setting, despite evidence-based
guidelines recommending screening in all patients who meet criteria. Genetic mutations, such as the BRCA1/2
gene mutations, drastically increase breast and ovarian cancer risk in patients. Current cancer risk assessment
rates and genetic testing rates are both very inconsistent month to month; assessment rates range from 12.19%
to 63.47% and genetic testing rates range from 22.73% to 60.00%. The mean genetic testing rate is 40.11% and
the mean cancer risk assessment rate is 33.65%; both display low adherence to evidence-based guidelines.
Data shows that many patients are not completing cancer risk assessments and that not every high-risk patient
is completing genetic testing.

BACKGROUND:
The USPSTF and the NCCN provide evidence-based guidelines to guide appropriate cancer risk assessment,
genetic testing, and referrals to genetic counseling for breast and ovarian cancer related gene mutations.
Adherence to guidelines improves patient safety and outcomes through early detection and cancer prevention
interventions. Identification of harmful gene mutations can save the lives of patients and their family members.
The USPSTF guidelines state that women who present with personal or family history associated with a higher
risk of carrying a BRCA1/2 gene mutation should first be screened with a validated cancer risk assessment tool
to determine risk level, then receive genetic testing and genetic counseling if classified as high-risk.
PCPs are at the front lines of preventative care in the community and should participate in preventative
genomic care. Genetic testing rates are significantly lower within primary care compared to oncology.
Preventative care measures are intended to aid in identifying and reducing risk prior to receiving a cancer
diagnosis and needing oncology services. Early detection and prevention of cancer is hindered when harmful
gene mutations have not yet been identified. PCPs need to follow evidence-based guidelines and participate in
safe preventative care through cancer risk assessment, genetic testing, and referrals to genetic counselors.
ASSESSMENT:
This gap in clinical practice leaves the high-risk population vulnerable to potential missed or late cancer
diagnosis, causing harmful outcomes. PCPs are not practicing safe care when they allow patients carrying
harmful gene mutations to participate in preventative care measures recommended to the average population.
BRCA1/2 mutation carriers need additional risk-reducing interventions to ensure early detection and
prevention of breast and ovarian cancer. Current system failures have been identified related to completing
cancer risk assessments, completing genetic testing, and patient follow-up for results and care management.
RECOMMENDATION:
The implementation of the CRA/GT-Protocol is intended to limit system barriers and increase genetic testing
rates by addressing the three identified practice gaps including: inconsistent cancer risk screening rates,
inconsistent genetic testing rates, and inconsistent patient tracking and follow-up to ensure testing is completed
and results are reviewed with a provider for proper care management. The goal of this protocol is to directly
increase patient safety and outcomes by increasing genetic testing rates among high-risk individuals and
promoting guideline adherence.
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